Trial Profile
A phase II study of a low dose every 3 weeks Abraxane for metastatic or recurrent breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2018
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 04 Feb 2018 Status changed from active, no longer recruiting to completed.
- 03 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 31 Jan 2012 New trial record